March 6, 2026 – Cupertino, California – CARPL.ai, the world's largest radiology AI marketplace and enterprise platform, today announced a new partnership with Medica Group, the UK and Ireland’s leading teleradiology provider.
Together, both organisations will bring safe and clinically validated AI into everyday diagnostic practice across the UK, helping patients receive faster and more accurate diagnoses, whilst easing the pressure on NHS services. This marks a significant shift in how AI is validated and embedded into live clinical workflows at a national level.
Medica’s network of more than 850 specialist reporters deliver over 2.5 million radiology reports each year for the majority of NHS Trusts. With CARPL.ai, Medica will now be able to rapidly evaluate AI solutions for Trusts helping clinicians quickly identify conditions such as potential brain bleeds, lung cancer, fractures, and blood clots on the lung (pulmonary emboli). The tools, starting with the deployment of Radiobotics’ RBfracture for advanced fracture detection, support radiologists in highlighting subtle abnormalities, prioritise patients who may require urgent attention, helping to improve patient outcomes.
Alongside Medica’s existing AI deployments, the platform not only allows Medica to test and select the best-performing AI applications without disrupting existing workflows, but also provides ongoing and extensive monitoring of data to support post-market surveillance of each clinical tool.
Working together, the teams at Medica, CARPL.ai, and Radiobotics were able to deploy, test, fine-tune, and go live with a clinical tool in less than a month. Radiobotics’ RBfracture processes x-rays to look for fractures, dislocations and effusions. The deployment supports high-volume study processing of up to 2,500 examinations per day. By embedding RBfracture into the workflow, advanced fracture detection is now delivered at scale, supporting faster clinical decision-making and reducing pressure on NHS services.
“This is a major win for both Radiobotics and CARPL.ai,” added Peter Ulvskjold, CEO of Radiobotics. “We’re excited to bring our specialised MSK expertise to a national scale, helping to optimise services and ultimately improve patient care across the UK.”
Beyond marketplace applications, Medica is leveraging CARPL.ai as an integration and orchestration layer for AI vendors with whom it maintains independent relationships, creating a cohesive operational environment across its AI ecosystem.
Kevin Terrins, Group Director of Corporate Development at Medica Group, said: “Clinical AI is advancing rapidly, and CARPL.ai has proven to be an exceptionally capable and collaborative partner in helping us deploy safe AI tools across our services. Their platform enables us to validate and continually monitor AI in a way that supports our radiologists and ultimately improves patient outcomes. For Trusts, it provides the NHS with rapid access to more than 200 licensed and validated AI tools in a controlled, safe environment, all without the need for additional procurement. We’ve been particularly impressed by their ability to scale to the volumes we require and to respond quickly to evolving clinical needs. Alongside using applications from their marketplace, we also use the CARPL.ai platform to support AI deployments where we have direct relationships with suppliers. Their flexibility and patient‑first approach make them an ideal partner on our AI journey.”
Vidur Mahajan, CEO of CARPL.ai, said: "We are proud to partner with Medica to deploy AI across their national network. Through the platform approach, Medica can evaluate, integrate, and monitor multiple AI applications in clinical practice, ensuring every patient across the UK benefits from the highest standard of safe, reliable care.”
Looking ahead, Medica and CARPL.ai plan to explore expansion into additional clinical pathways, and leverage CARPL’s universal AI widget for the creation of a structured feedback loop, providing real-world usage insights and contributing to ongoing monitoring of deployed models.
As the NHS continues to face sustained pressure on imaging capacity, Medica will be scaling the adoption of AI across multiple modalities within a single, integrated platform, helping to make sure Medica is well-positioned to support healthcare providers and deliver timely, accurate diagnostic reports that directly support patient care.
About Medica
Medica is the UK’s leading teleradiology provider, working in partnership with more than half of NHS Trusts to deliver AI-enabled diagnostic services at a national scale. Its clinically governed AI is embedded within existing NHS workflows, enabling rapid adoption without the need for new systems, complex procurement processes, or additional capital investment.
Medica supports faster, safer clinical decision making across imaging pathways, with demonstrated impact in emergency care through its award-winning AI for the detection of brain haemorrhage in stroke and major trauma. This is underpinned by a robust, enterprise-level approach to AI deployment, continuous performance monitoring, and clinical oversight.
About Radiobotics
Founded in 2017, Radiobotics is an award-winning Danish MedTech company dedicated to advancing musculoskeletal (MSK) radiology with AI-powered solutions. Radiobotics’ flagship solution, RBfracture™, is designed to support Emergency and Radiology with highly accurate detection of trauma-related findings, including fractures, dislocations, lipohemarthrosis, and effusion. Radiobotics’ commitment to delivering precise, expert-level care in MSK imaging 24/7, regardless of time, infrastructure, or staffing constraints, is reflected in its close collaboration with leading clinical institutions, including partnering with Oxford University Hospital (OUH) on the world’s first and largest randomised clinical trial evaluating radiology AI in urgent care as well as achieving NICE approval for use in urgent care settings across the NHS.
About CARPL.ai
CARPL.ai is the world's largest radiology AI marketplace and platform offering 250+ applications from 90+ AI Partners. With regulatory clearances across multiple regions that include the FDA (USA), CE (EU), ANVISA (Brazil), TGA (Australia) and HSA (Singapore), CARPL.ai enables radiologists and researchers to seamlessly access, assess, and integrate radiology AI solutions into their clinical practice. CARPL.ai provides a single user interface, a single data channel, and a single procurement channel for the testing, deployment, and monitoring of AI solutions in clinical radiology workflows. The CARPL.ai platform integrates with leading PACS systems, including Agfa HealthCare, DeepHealth, Intelerad, Philips, Ramsoft, Paxera Health, amongst others, ensuring end-to-end interoperability across imaging environments. From research validation to clinical deployment, CARPL.ai serves as the orchestration layer for responsible, scalable AI adoption in radiology.
